Quest Diagnostics…
USUSDQuest Diagnostics Incorporated (LSE:0KSX) — Medical Specialities. Aantal beurzen waarop de aandelen van het bedrijf worden verhandeld: 2. Op deze pagina — koers en grafiek, dividenden, grootste aandeelhouders en historiek van het aantal aandelen.
Over het bedrijf
- Website
- questdiagnostics.com
- Beleggersrelaties
- ir.questdiagnostics.com/overview/default.aspx
- Sector
- Health Care · Medical Specialities
- Hoofdkantoor
- Madison, United States
- CEO
- Steve Rusckowski
- Werknemers
- 46 000
- Opgericht
- 1967
- Beursgenoteerd sinds
- 29.01.2018 (LSE:0KSX)
- Uitstaande aandelen
- 110.37 mln. per 2026-07-15
- Free float
- 109.81 mln.
- Marktkapitalisatie
- 25.21 mld. USD
- Insiders
- 0.43%
- Institutionele beleggers
- 98.9%
- Branche (SIC)
- Services-Medical Laboratories
- LEI
- 8MCWUBXQ0WE04KMXBX50
- Uitkeringsratio
- 34.2%
- FCF
- 1.35 mld. USD27%
- Schuld
- 5.64 mld. USD3.7 jr FCF
- Dividendreeks
- 22 jr
- Winst, FCF en uitbetaalde dividenden — voor de 12 maanden tot 30.06.2026 (het laatste rapport van het bedrijf).
Beschrijving
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Dividenden
Quest Diagnostics Incorporated (DGX) betaalt elk kwartaal dividend uit. In de afgelopen 12 maanden werd 3.38 USD per aandeel betaald (betalingen: 4). Dat is ongeveer 1.46% van de huidige aandelenkoers. Op basis van de betalingsgeschiedenis wordt de volgende ex-dividenddatum verwacht rond 05.01.2027. Ononderbroken dividendgeschiedenis: 22 jaar.
| Ex-datum | Uitbetaling | Bedrag | % | Type | Ticker |
|---|---|---|---|---|---|
| 2026-10-06 | 2026-10-21 | 0.8600 USD | 0.4/1.5 % | per kwartaal | US:DGX |
| 2026-07-08 | 2026-07-22 | 0.8600 USD | 0.4/1.4 % | per kwartaal | US:DGX |
| 2026-04-06 | 2026-04-20 | 0.8600 USD | 0.4/1.4 % | per kwartaal | US:DGX |
| 2026-01-13 | 2026-01-28 | 0.8000 USD | 0.3/1.4 % | per kwartaal | US:DGX |
| 2025-10-03 | 2025-10-20 | 0.8000 USD | 0.3/≈1.4 % | per kwartaal | US:DGX |
| 2025-07-07 | 2025-07-21 | 0.8000 USD | 0.3/≈1.4 % | per kwartaal | US:DGX |
| 2025-04-07 | 2025-04-21 | 0.8000 USD | 0.3/≈1.4 % | per kwartaal | US:DGX |
Nieuws deze week
Nog geen nieuws van de website van het bedrijf.
Grootste aandeelhouders
| Houder | Belang | Aandelen | Rapportdatum |
|---|---|---|---|
| Blackrock Inc. | 8.4% | 9.28 mln. | 2026-06-30 |
| Vanguard Capital Managem… | 6.55% | 7.23 mln. | 2026-06-30 |
| Vanguard Portfolio Manag… | 5.55% | 6.13 mln. | 2026-06-30 |
| State Street Corporation | 5% | 5.52 mln. | 2026-06-30 |
| Price (T.Rowe) Associate… | 4.93% | 5.44 mln. | 2026-06-30 |
| Boston Partners | 4.3% | 4.74 mln. | 2026-06-30 |
| JPMORGAN CHASE & CO | 3.19% | 3.52 mln. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.18% | 3.51 mln. | 2026-06-30 |
| Geode Capital Management… | 2.84% | 3.14 mln. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.6% | 2.87 mln. | 2026-06-30 |
| Morgan Stanley | 2.23% | 2.46 mln. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.17% | 2.4 mln. | 2026-06-30 |
| Edgepoint Investment Gro… | 2.04% | 2.25 mln. | 2026-06-30 |
| iShares Trust-iShares Co… | 1.33% | 1.47 mln. | 2026-08-31 |
| Fidelity Concord Street… | 1.3% | 1.43 mln. | 2026-07-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.23% | 1.36 mln. | 2026-08-31 |
| John Hancock Funds III-D… | 1.09% | 1.2 mln. | 2026-07-31 |
| JPMorgan Trust II-JPMorg… | 1.04% | 1.15 mln. | 2026-06-30 |
| T. Rowe Price Dividend G… | 1% | 1.11 mln. | 2026-06-30 |
| John Hancock Funds III-D… | 0.96% | 1.06 mln. | 2026-07-31 |
| DAVIS J E CAUSEY (Chief… | ≈0.13% | 142 423 | 2026-03-04 |
| DAVIS JAMES E (Chief Exe… | ≈0.11% | 122 423 | 2026-09-01 |
| DOHERTY CATHERINE T (Off… | ≈0.06% | 71 624 | 2026-03-05 |
| PREVOZNIK MICHAEL E (Gen… | ≈0.04% | 42 337 | 2026-08-28 |
| DEPPE MICHAEL J (Officer… | ≈0.03% | 35 196 | 2026-03-04 |
| SAMAD SAMER ABDUL (Chief… | ≈0.03% | 33 478 | 2026-07-22 |
| RING TIMOTHY M (Director… | ≈0.03% | 31 140 | 2026-05-20 |
| PFEIFFER GARY M (Directo… | ≈0.03% | 31 005 | 2026-05-20 |
| MAIN TIMOTHY L (Director… | ≈0.02% | 27 460 | 2026-07-22 |
| GREGG VICKY B (Director) | ≈0.02% | 18 386 | 2026-07-22 |
